Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Major study: Bioartificial liver reduces mortality by 44 percent in acute liver-failure patients

22.04.2004


In a major study conducted at 20 centers in the United States and Europe, a bioartificial liver developed by researchers at Cedars-Sinai Medical Center reduced mortality significantly among patients suffering from acute liver failure, the dramatic loss of liver function that can cause death in days or even hours. Study results are published in the May issue of Annals of Surgery.



This is the first large-scale, prospective, randomized, multi-center trial examining the effectiveness of any artificial liver support. Currently, standard treatment consists of intensive, supportive care intended to keep patients alive long enough that the liver might recover spontaneously or a donor organ will become available for transplantation.

Acute liver failure is diagnosed when a massive loss of hepatic cells causes severe liver dysfunction and life-threatening complications within six months of the onset of symptoms. When this dysfunction occurs within the first eight weeks after onset, liver failure is termed "fulminant." When it occurs in the period between eight weeks and six months, it is "subfulminant" (or late-onset). In either case, few patients survive the resulting fluid buildup in the brain, catastrophic bacterial infections, multi-organ failure, blood-clotting abnormalities, respiratory problems, kidney failure or other potential complications. It is estimated, in fact, that up to 80 percent of patients will die unless they receive a liver transplant.


In the United States, the causes of many cases of acute liver failure are never identified, although precipitating factors can include toxic poisoning, medication interactions or overdoses, metabolic disorders, and some types of viral hepatitis.

Achilles A. Demetriou, MD, PhD, Chairman of Surgery at Cedars-Sinai and the study’s principal investigator, has been pursuing treatments for acute liver diseases since 1976 when he began studying liver cells at the National Institutes of Health. He continued his research at Vanderbilt University, coming to Cedars-Sinai in 1992 to launch the country’s first unit devoted to managing massive acute liver failure.

The study included 147 patients who suffered from fulminant/subfulminant hepatic failure and 24 patients whose livers had failed after transplantation. Of the 171 total patients, 85 received BAL treatment, while 86 received standard supportive care.

For the entire patient population, survival at 30 days was 71 percent among the BAL group, compared with 62 percent for those receiving traditional care. Analyzing results among only the 147 patients with fulminant/subfulminant hepatic failure, the researchers found that the BAL provided a 44 percent reduction in mortality.

During a treatment, blood is drawn from a vein through a catheter. Blood plasma is separated from the serum and pumped through a charcoal column and an oxygenator before it reaches the bioreactor – a tube-shaped device containing a fiber membrane and 7 billion liver cells from pigs. These cells are isolated, cryopreserved (frozen) and thawed according to techniques originally developed by the Cedars-Sinai researchers.

"The blood is removed at a fixed rate, detoxified and treated in the various components of the bioartificial liver, reconstituted, and returned to the patient at the same rate at which it is being removed," said Dr. Demetriou. "Just before the patient is treated, the pig liver cells are thawed, reactivated and attached to small beads that serve as a scaffold for the cells. We put the cells and beads into the cartridge, and when the patient’s plasma flows through the fibers, the pig liver cells detoxify it and replace missing nutrients."

Each treatment is completed in about six hours, and the benefits last about 24 hours. In most cases of acute liver failure, a series of treatments may need to continue for only a few days or several weeks. "Typically, within that time the patient’s condition is going to improve because his or her own liver kicks in or a liver will be available for transplantation," Dr. Demetriou said.


The study was funded by Circe Biomedical Inc.

Cedars-Sinai is one of the largest nonprofit academic medical centers in the Western United States. For the fifth straight two-year period, it has been named Southern California’s gold standard in health care in an independent survey. Cedars-Sinai is internationally renowned for its diagnostic and treatment capabilities and its broad spectrum of programs and services, as well as breakthroughs in biomedical research and superlative medical education. The Medical Center ranks among the top 10 non-university hospitals in the nation for its research activities.

Sandra Van | Van Communications
Further information:
http://www.csmc.edu/

More articles from Health and Medicine:

nachricht Satellites, airport visibility readings shed light on troops' exposure to air pollution
09.12.2016 | Veterans Affairs Research Communications

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Electron highway inside crystal

Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.

Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Researchers identify potentially druggable mutant p53 proteins that promote cancer growth

09.12.2016 | Life Sciences

Scientists produce a new roadmap for guiding development & conservation in the Amazon

09.12.2016 | Ecology, The Environment and Conservation

Satellites, airport visibility readings shed light on troops' exposure to air pollution

09.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>